API | siremadlin

siremadlin Report issue

Small molecule Experimental

AACT PubChem

Active Ingredient History

NOW

Chemistry

SMILES: COc1ncc(-c2nc3c(n2C(C)C)[C@H](c2ccc(Cl)cc2)N(c2cc(Cl)cn(C)c2=O)C3=O)c(OC)n1
InChIKey: AGBSXNCBIWWLHD-FQEVSTJZSA-N
Mol. Mass: 555.42
ALogP: 4.69 Partition coefficient
ChEMBL Molecule:
siremadlin

More Chemistry

Pharmacology

Mechanisms of Action:
- E3 ubiquitin-protein ligase Mdm2 (Homo sapiens) ^UniProt
- Cellular tumor antigen p53 (Homo sapiens) ^UniProt
- E3 ubiquitin-protein ligase Mdm2 (Homo sapiens) ^UniProt
Multi-specific: Missing data
Black Box: No
Availability: Missing data
Delivery Methods: Missing data
Pro Drug: No

hdm201

Organizations (7)

Research & Development (7)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Marketing (0)

Organization	Org Type	FDA approvals	Clinical Trials involvement	Org ID	Force Sort

Indications (11)

Approved Indications (0)

Experimental Indications - Clinical Trial Phases 1-4 (11)

Colorectal Neoplasms (Phase 1)

Hematopoietic Stem Cell Transplantation (Phase 1/Phase 2)

Leukemia, Myeloid, Acute (Phase 1/Phase 2)

Liposarcoma (Phase 1/Phase 2)

Liver Diseases (Phase 1)

Myelodysplastic Syndromes (Phase 1)

Neoplasm Metastasis (Phase 1/Phase 2)

Neoplasms (Phase 2)

Neuroblastoma (Phase 1)

Primary Myelofibrosis (Phase 1/Phase 2)

Sarcoma (Phase 1/Phase 2)

Overview

Highest Phase: Phase 2
# of Trials: 13
# of Trial Organizations: 7

Trials by Phase

Trial	Phase	Start Date	Organizations	Indications

Feedback

Data collection and curation is an ongoing process for CDEK - if you notice any information here to be missing or incorrect, please let us know! When possible, please include a source URL (we verify all data prior to inclusion).

Report issue